Alignment Healthcare Inc (ALHC) valuation
Alignment Healthcare P/E ratio history
Alignment Healthcare trades at 36.4 times its earnings over the last twelve months and 13.8 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $19.75 | $0.00 | n/m |
| Dec 31, 2024 | $11.25 | -$0.67 | n/m |
| Dec 31, 2023 | $8.61 | -$0.79 | n/m |
| Dec 31, 2022 | $11.76 | -$0.83 | n/m |
| Dec 31, 2021 | $14.06 | -$1.15 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Alignment Healthcare valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Alignment HealthcareALHC | $1.51B | 36.4 | 13.8 | 0.3 |
| Mineralys TherapeuticsMLYS | $1.50B | — | — | — |
| Ocular TherapeutixOCUL | $1.53B | — | — | 29.3 |
| NovocureNVCR | $1.53B | — | — | 2.1 |
| Teladoc HealthTDOC | $1.54B | — | — | 0.6 |
| InnovivaINVA | $1.57B | 4.9 | 9.4 | 3.6 |
| Pennant GroupPNTG | $1.45B | 45.8 | 27.9 | 1.3 |
| First Tracks BiotherapeuticsTRAX | $1.57B | — | — | — |
| Phibro Animal HealthPAHC | $1.58B | 16.0 | 11.1 | 1.0 |
| Peer median | 16.0 | 11.1 | 1.7 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ALHC financials · ALHC returns
No forecast, no recommendation. This page describes Alignment Healthcare Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.